Find in Library

In the article, “Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease”,[1] which appeared in Volume 7, Issue 1 of  Global & Regional Health Technology Assessment, the number of patients undergoing treatment with tocilizumab and anakinra displayed in Table V (column Current Scenario) was inadvertently inverted. Affected data have been corrected in the article now appearing online. The authors apologize for any inconvenience caused to the readers by these changes, which do not affect the final results of the study.  The final version of this article is available online and includes a reference to this correction.